Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Disease progression and neuroscience.

Literature DB >> 23592038

Disease progression and neuroscience.

Abstract

The concepts of disease progression are discussed in the context of neurological disorders. The importance of understanding the time course of the response to inactive (placebo) treatment is discussed. Disease progression and response to placebo treatment both need to be considered before drug effects can be reliably identified. Criteria for distinguishing between symptomatic and disease modifying drug effects are proposed and used to interpret the results of clinical trials in pain, depression, schizophrenia, stroke, Alzheimer's disease and Parkinson's disease.

Entities: Disease

Mesh：

Substances：
Neuroprotective Agents

Year: 2013 PMID： 23592038 DOI： 10.1007/s10928-013-9316-2

Source DB: PubMed Journal: J Pharmacokinet Pharmacodyn ISSN： 1567-567X Impact factor: 2.745

46 in total

1. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.

Authors: Thuy C Vu; John G Nutt; Nicholas H G Holford
Journal: Br J Clin Pharmacol Date: 2012-08 Impact factor: 4.335

2. Interpreting the results of Parkinson's disease clinical trials: time for a change.

Authors: Nick H G Holford; John G Nutt
Journal: Mov Disord Date: 2011-03-02 Impact factor: 10.338

Review 3. Rates of change of common measures of impairment in senile dementia of the Alzheimer's type.

Authors: J A Yesavage; S L Poulsen; J Sheikh; E Tanke
Journal: Psychopharmacol Bull Date: 1988

Review 4. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

Authors: S Fahn
Journal: Arch Neurol Date: 1999-05

5. Disease progression meta-analysis model in Alzheimer's disease.

Authors: Kaori Ito; Sima Ahadieh; Brian Corrigan; Jonathan French; Terence Fullerton; Thomas Tensfeldt
Journal: Alzheimers Dement Date: 2009-07-09 Impact factor: 21.566

6. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

Authors: N H Holford; K E Peace
Journal: Proc Natl Acad Sci U S A Date: 1992-12-01 Impact factor: 11.205

Review 7. Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review.

Authors: Winfried Häuser; Claas Bartram; Eva Bartram-Wunn; Thomas Tölle
Journal: Clin J Pain Date: 2012-06 Impact factor: 3.442

8. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.

Authors: Robert A Hauser; Nicholas H G Holford
Journal: Mov Disord Date: 2002-09 Impact factor: 10.338

9. The natural history of asymptomatic carotid artery disease.

Authors: R W Bock; A C Gray-Weale; P A Mock; M App Stats; D A Robinson; L Irwig; R J Lusby
Journal: J Vasc Surg Date: 1993-01 Impact factor: 4.268

10. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.

Authors: Berend Arnold Ploeger; Nicholas H G Holford
Journal: Pharm Stat Date: 2009 Jul-Sep Impact factor: 1.894

3 in total